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Introduction: The aim of this study was to investigate the association of adverse events (AEs) during targeted
temperature management (TTM) and other AEs and concomitant treatments during the advanced critical care
period with poor neurological outcome at hospital discharge in adult out-of-hospital cardiac arrest (OHCA) patients.
Methods: This was a retrospective study using Korean Hypothermia Network registry data of adult OHCA patients
treated with TTM in 24 teaching hospitals throughout South Korea from 2007 to 2012. Demographic characteristics,
resuscitation and post-resuscitation variables, AEs, and concomitant treatments during TTM and the advanced critical
care were collected. The primary outcome was poor neurological outcome, defined as a cerebral performance
category (CPC) score of 3–5 at hospital discharge. The AEs and concomitant treatments were individually entered
into the best multivariable predictive model of poor neurological outcome to evaluate the associations between each
variable and outcome.
Results: A total of 930 patients, including 704 for whom a complete dataset of AEs and covariates was available for
multivariable modeling, were included in the analysis; 476 of these patients exhibited poor neurological outcome
[CPC 3 = 50 (7.1 %), CPC 4 = 214 (30.4 %), and CPC 5 = 212 (30.1 %)]. Common AEs included hyperglycemia (45.6 %),
hypokalemia (31.3 %), arrhythmia (21.3 %) and hypotension (29 %) during cooling, and hypotension (21.6 %) during
rewarming. Bleeding (5 %) during TTM was a rare AE. Common AEs during the advanced critical care included
pneumonia (39.6 %), myoclonus (21.9 %), seizures (21.7 %) and hypoglycemia within 72 hours (23 %). After adjusting
for independent predictors of outcome, cooling- and rewarming-related AEs were not significantly associated with
poor neurological outcome. However, sepsis, myoclonus, seizure, hypoglycemia within 72 hours and anticonvulsant
use during the advanced critical care were associated with poor neurological outcome [adjusted odds ratios
(95 % confidence intervals) of 3.12 (1.40–6.97), 3.72 (1.93–7.16), 4.02 (2.04–7.91), 2.03 (1.09–3.78), and 1.69 (1.03–2.77),
respectively]. Alternatively, neuromuscular blocker use was inversely associated with poor neurological outcome
(0.48 [0.28–0.84]).
Conclusions: Cooling- and rewarming-related AEs were not associated with poor neurological outcome at hospital
discharge. Sepsis, myoclonus, seizure, hypoglycemia within 72 hours and anticonvulsant use during the advanced
critical care period were associated with poor neurological outcome at hospital discharge in our study.* Correspondence: emsky@catholic.ac.kr
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Out-of-hospital cardiac arrest (OHCA) is an important
public health problem in industrialized countries. In the
United States, Europe, and South Korea, the estimated
incidence of emergency medical services (EMS)-treated
OHCA among individuals of any age is 5.7, 38, and 32.7
per 100,000 persons, respectively, and the median rate of
survival to hospital discharge is 10.6 %, 10.7 %, and
3.7 %, respectively [1–3]. One of the worst complications of
sudden cardiac arrest is hypoxic ischemic encephalopathy.
Hypoxic ischemic encephalopathy after cardiac arrest
results in death or disability in 50 % of patients who
exhibit restoration of a pulse [4, 5]. Since positive
results of a quasi-randomized controlled trial and a
randomized controlled trial were reported in 2002,
targeted temperature management (TTM) has been
accepted as the only intervention shown in the last
decade to improve outcomes for patients resuscitated
from OHCA [6, 7]. Following these landmark studies,
many observational studies have reported the effectiveness
of TTM, and TTM is recommended as a component of
routine post-cardiac arrest care in the international
guidelines and a consensus report of five critical care
societies [8–10]. Recently, well-performed, large ran-
domized controlled trials also highlighted that target-
ing a temperature of 36 °C gives equal results as targeting
a temperature of 33 °C [11–13].
Induced hypothermia may cause various physiological
changes as well as adverse events (AEs) [14, 15]. Although
AEs commonly occur during TTM and the advanced
critical care period, the incidence of most AEs is not
significantly different between induced hypothermia
and normothermia treatment [16, 17]. Although some
investigators have reported an association between
AEs recorded during critical care and mortality, few
studies have investigated the relationship between AEs
and neurological outcomes in patients with return of
spontaneous circulation (ROSC) after OHCA [18–20].
Furthermore, most previous studies have been performed
in Western countries, which have relatively high bystander
cardiopulmonary resuscitation (CPR) rates and well-
established EMS systems and where the withdrawal of
life-sustaining treatment (WLST) is permitted according
to the legislation.
The aim of this study was to investigate the association
of cooling-related AEs, rewarming-related AEs, other
AEs, and concomitant treatments during the advanced
critical care period with poor neurological outcome at
the time of hospital discharge in adult OHCA patients
who received TTM in South Korea; the baseline character-
istics of South Korean adult OHCA patients are different
from those of adult OHCA patients in Western countries,
and WLST based on prognostication is not yet permitted
in South Korea.Materials and methods
Patients
This was a multicenter, retrospective, registry-based study.
This study used the Korean Hypothermia Network
(KORHN) registry data. The KORHN, a multicenter
clinical research consortium for TTM in South Korea,
was organized in 2011 and performed the multicenter
retrospective registry project in 2012. The KORHN
investigators retrospectively collected data from OHCA
patients treated with TTM and advanced critical care at
24 teaching hospitals throughout South Korea from 2007
to 2012. The 24 centers used their own protocol for TTM,
but the protocols of most centers included the same
parameters of TTM (target temperature of 33 °C, 24-hour
maintenance, and controlled normothermia for 72 hours
after ROSC). The institutional review board of each
institution approved the study protocol before data
collection. The name of ethics bodies and site princi-
pal investigators are listed in the Acknowledgements
section. The institutional review boards waived the require-
ment to obtain informed consent due to the retrospective
nature of the study.
Adult (≥18 years) OHCA patients treated with TTM
after ROSC were included in the study. Traumatic
cardiac arrest patients were excluded. The case report form,
standard definitions of 87 variables, and an investigator
manual were developed based on a literature review and a
consensus of the study investigators (see Additional file 1).
The definitions and time points of the variables followed
the Utstein recommendations [21, 22]. The registry data
were collected from reviews of medical charts or electronic
medical records. The data collected from each hospital
were verified for completeness by the site principal investi-
gator and were recorded in a web-based data registration
system by the site clinical research coordinator. A data
manager and three clinical research associates moni-
tored and regularly reviewed data quality. The site principal
investigators or site clinical research coordinators were
contacted using the query function in the system or dir-
ectly by phone to clarify data.
Data collection
We collected data, including demographic characteristics,
resuscitation variables, post-resuscitation variables, and
AEs and concomitant treatments during TTM and the
advanced critical care period. The detailed definitions of
the variables and other items included in the registry are
described in an Additional file (see Additional file 2) and
were reported in an article describing the KORHN registry
project [23]. The AEs were divided into cooling-related,
rewarming-related, and other AEs during the advanced
critical care period. The considered cooling-related and
rewarming-related AEs were those which were commonly
reported in the literature and were typically attributed to
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was derived from the American Heart Association
adult immediate post-cardiac arrest care algorithm
[8]. The advanced critical care period was defined as
days 1–7 after ROSC, which was the definition used
in previous AE studies [11, 24]. We have included
the period as a figure form in a practical manual of
post-cardiac arrest care for hospital providers devel-
oped by the KORHN. We added the figure in an
Additional file (see Figure S1 in Additional file 3).
Overcooling (<32 °C), bradycardia (<40 beats/min),
tachyarrhythmia, hypokalemia (<3.0 mEq/L), hypergly-
cemia (>180 mg/dL), bleeding, and hypotension were
collected as cooling-related AEs. Rebound hyperthermia
(>38 °C within 24 hours of the cessation of cooling),
arrhythmia, hyperkalemia (>5.0 mEq/L), hypoglycemia
(<80 mg/dL), bleeding, and hypotension were collected
as rewarming-related AEs. Tachyarrhythmia during
cooling was defined as newly developed tachyarrhythmia
during cooling except for sinus tachycardia. Bleeding was
defined as any site of bleeding associated with cooling and
rewarming. Hypotension was defined as systolic blood
pressure (SBP) <90 mmHg or mean arterial pressure
(MAP) <60 mmHg for at least 30 min or requiring
supportive measures (fluid loading and treatment with
a vasopressor or inotropic drug or both types of drugs) to
maintain the SBP >90 mmHg or the MAP >60 mmHg
during cooling and rewarming.
Sepsis, pneumonia, myoclonus and seizure occurring
during the advanced critical care period that could
not be clearly categorized as typical cooling-related or
rewarming-related AEs were categorized as other AEs.
All hypoglycemic events (defined as <80 mg/dL within
72 hours after ROSC and collected in the registry)
occurring during the advanced critical care period
were categorized as other AEs. The use of analgesics,
sedatives, neuromuscular blockers (NMBs), anticon-
vulsants and insulin during TTM and the advanced
critical care period was categorized as concomitant
treatment. Sepsis was defined as a clinical syndrome
defined by the presence of both documented or sus-
pected infection and systemic inflammatory response
syndrome; these cases were categorized as sepsis, severe
sepsis, or septic shock [25]. Pneumonia was diagnosed
based on the following four clinical criteria without
microbiological confirmation: new or progressive con-
solidation on a chest radiograph, fever, leukocytosis,
and the presence of purulent tracheobronchial secretions
[19]. Seizure was diagnosed based on either clinically
involuntary movements with epileptiform discharges
on electroencephalography (EEG) or epileptiform dis-
charges alone on EEG. Myoclonus was defined as
clinically involuntary movement without epileptiform
discharges on EEG.Outcome measures
The goal of our study was to examine the association
between AEs and poor neurological outcome at hospital
discharge. Poor neurological outcome was defined as a
cerebral performance category (CPC) scale score of 3–5.
Based on the traditional criteria, CPC 3 indicates severe
cerebral disability (conscious but disabled and dependent),
CPC 4 indicates coma or a vegetative state (unconscious),
and CPC 5 indicates brain death or death [26]. The CPC
scores at hospital discharge, which were recorded in the
medical charts and the electronic medical records by
attending physicians or independent neurologists, were
collected. If the score was not recorded, site investi-
gators abstracted these data from the medical records
by consensus.
Statistical analysis
Continuous variables are expressed as the means and
standard deviations or the medians and interquartile
ranges according to normal distributions, and categorical
variables are expressed as numbers and percentages. We
used the Wilcoxon rank sum test or the t test and the
chi-squared test as appropriate for univariate comparisons
of the baseline characteristics between patients with good
and poor neurological outcome. First, we determined the
clinical variables that were independently associated
with functional outcome. Second, we determined the
association of cooling-related AEs, rewarming-related
AEs, and other AEs during the advanced critical care
period with functional outcome, adjusting for the clinical
variables identified during the first step.
A multivariate analysis of the relationship between
functional outcome and the baseline characteristics was
performed using a stepwise logistical regression method,
which utilizes a combination of forward and backward
selection for multivariable predictive modeling. Variables
displaying p ≤0.15 based on univariate analysis were con-
sidered as candidates for inclusion in the multivariable
predictive model. Continuous variables entered into the
model included age (in years), time from arrest to ROSC
(in minutes), time from arrest to initiation of cooling
(in minutes), time from arrest to 34 °C (in minutes),
and rewarming time (in minutes). Dichotomous variables
included sex (male as reference), previously unhealthy
(absence of the listed diseases as reference), underlying
disease (absence of disease as reference), unwitnessed
arrest (witnessed as reference), no bystander CPR
(bystander CPR as reference), non-shockable initial rhythm
(ventricular fibrillation/pulseless ventricular tachycardia as
reference), non-cardiac cause of arrest (cardiac cause of
arrest as reference), initial Glasgow coma scale (GCS)
score (<5 as reference), initial presence of the pupillary light
reflex (absence of the pupillary light reflex as reference),
ST-segment elevation myocardial infarction (STEMI)
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genic shock as reference), and hospital interventions
(no intervention as reference). The results are presented
as the mean or median differences with p values or odds
ratios (ORs) with 95 % confidence intervals (CIs). The
goodness-of-fit of the final model was assessed using the
Hosmer-Lemeshow test with chi-square analysis and
max-rescaled R [2]. To assess the predictiveness of
the final model, we calculated the area under the receiver
operating characteristic curve (AUC). As a sensitivity
analysis, we assessed the adequacy of the final model
including all available data from 930 subjects.
The AEs and the concomitant treatments were indi-
vidually entered into the multivariable predictive model
adjusting for the confounders of outcome to evaluate
their association with functional outcome. The results
are presented as adjusted ORs with 95 % CIs. For
exploratory analyses, we performed univariate logistic
regression analyses to evaluate the association between
each AE and the clinical variables. Additionally, we
performed a sensitivity analysis using the data from the
patients who survived until sedation was withdrawn
(approximately 3 days after ROSC) to focus on the
association between the AEs and functional outcome
among these patients. The analyses were conducted using
SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Two-tailed tests of significance were used, and p <0.05 was
considered to be statistically significant in the analyses.
Results
Baseline patient characteristics and univariate
comparisons of the characteristics
A total of 930 patients from 24 hospitals were included
in the registry. The geographic distribution and the
number of patients enrolled in the 24 participating
centers were reported as a figure form in an article
describing the KORHN registry project [23]. We
added the figure in an Additional file (see Figure S2
in Additional file 3). Among these patients, 226 patients
for whom data were missing were excluded; as a result,
704 patients were included in the analysis (Fig. 1). Table 1
provides the baseline characteristics, including demo-
graphics, resuscitation variables, and post-resuscitation
variables, of the included patients and the univariate
comparisons of these characteristics between those
with good and poor neurological outcome. Of the 228
(32.4 %) patients with good neurological outcome,
193 (27.4 %) and 35 (4.9 %) patients were discharged
with CPC 1 and 2, respectively. Among the 476 (67.6 %)
patients with poor neurological outcome, 50 (7.1 %),
214 (30.4 %), and 212 (30.1 %) exhibited CPC of 3, 4,
and 5, respectively. In our study, surviving OHCA
patients were discharged after an average of 14–15 days at
the hospital.Multivariable predictive modeling of poor neurological
outcome
The best multivariable model for predicting poor neuro-
logical outcome at the time of hospital discharge included
nine independent variables (Table 2). The final model
showed the following characteristics: a Hosmer-Lemeshow
test: chi-square = 13.6, p= 0.093; max-rescaled R [2] = 0.659;
and AUC= 0.929. Based on a sensitivity analysis of 882
subjects for whom data for the variables were available, the
final model also performed well (Hosmer-Lemeshow test:
chi-square = 13.6, p = 0.714; max-rescaled R [2] = 0.655;
and AUC= 0.933).
Adverse events associated with poor neurological
outcome
The frequencies of TTM-related (cooling- and rewarming-
related), and other AEs during the advanced critical care
period and concomitant treatments during TTM and the
advanced critical care period, along with corresponding
odds ratios for poor neurological outcome, are presented in
Table 3. Table 4 shows the factors associated with selected
AEs based on univariate analysis.
TTM-related AEs
Overcooling, hyperglycemia, and hypotension during the
cooling period and hyperkalemia and hypotension during
the rewarming period were more frequently observed in
patients with poor neurological outcome than in patients
with good neurological outcome. However, after adjusting
for independent predictors of poor neurological outcome,
these AEs were not significantly associated with poor
neurological outcome.
Newly developed arrhythmia during TTM was observed
in 192 (27.3 %) patients and most frequently developed
during the cooling period. Bradycardia was more frequently
observed in patients with good neurological outcome based
on univariate analysis. However, after adjusting for
independent predictors of poor neurological outcome,
bradycardia was not significantly associated with poor
neurological outcome.
Bleeding developed in 35 patients (5 %) during TTM,
and 17 patients (2.4 %) required a transfusion. Among
these patients, cooling was stopped due to severe bleeding
for only 1 patient (0.1 %). Based on univariate analysis,
intra-aortic balloon pump (IABP) use, continuous renal
replacement therapy (CRRT), and cardiogenic shock
were associated with bleeding. There was no signifi-
cant difference in the incidence of bleeding between
patients with good and poor neurological outcome at
hospital discharge.
Other AEs during the advanced critical care period
Pneumonia and sepsis were associated with poor
neurological outcome based on univariate analysis. After
Fig. 1 Flow diagram of the patient selection process
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outcome, sepsis, but not pneumonia, was significantly
associated with poor neurological outcome.
Myoclonus, seizure, and hypoglycemia within 72 hours
after ROSC were associated with poor neurological out-
come based on univariate analysis. After adjusting for the
independent predictors of poor neurological outcome,
myoclonus, seizure, and hypoglycemia within 72 hours
after ROSC remained significantly associated with poor
neurological outcome.Concomitant treatment during TTM and the advanced
critical care period
Patients with poor neurological outcome were more
frequently treated with anticonvulsants or insulin than
those with good neurological outcome. After adjusting
for independent predictors of poor neurological out-
come, anticonvulsant use, but not insulin use, was
significantly associated with poor neurological outcome.
Alternatively, the use of analgesics, sedatives and NMBs
was inversely associated with poor neurological out-
come based on univariate analysis. After adjusting for
independent predictors of poor neurological outcome, only
NMB use was inversely associated with poor neurological
outcome.Sensitivity analysis of the patients who survived after
sedation was withdrawn
A total of 32 patients (4.5 %) died within 3 days after
ROSC. Based on sensitivity analysis of the remaining
672 patients, the best multivariable model for predicting
poor neurological outcome included the same nine inde-
pendent variables described above. This model displayed
the following characteristics: Hosmer-Lemeshow test:
chi-square = 7.5, p = 0.487; max-rescaled R [2] = 0.668; and
AUC = 0.930. The same four AEs and one concomitant
treatment were significantly associated with poor neuro-
logical outcome at hospital discharge based on univariate
and multivariate analyses (see Additional file 4).Discussion
In this multicenter, registry-based study of adult OHCA
patients treated with TTM, cooling-related or rewarming-
related AEs were not significantly associated with poor
neurological outcome at hospital discharge after adjusting
for significant predictors of poor neurological outcome.
However, sepsis, myoclonus, seizure, hypoglycemia within
72 hours after ROSC and anticonvulsant use during the
advanced critical care period were significantly associated
with poor neurological outcome at hospital discharge.
Based on sensitivity analysis of the 672 patients who
Table 1 Baseline patient characteristics
Patient characteristics Good neurological outcome
(CPC 1 and 2) n = 228 (32.4)
Poor neurological outcome
(CPC 3–5) n = 476 (67.6)
p
Background variables
Age, years 50 (40–60) 59 (47–71) <.001
Male 177 (77.6) 323 (67.9) 0.008
Previously healthya 130 (57.0) 178 (37.4) <.001
Myocardial infarction 13 (5.7) 26 (5.5) 0.897
Angina 19 (8.3) 29 (6.1) 0.270
Congestive heart failure 5 (2.2) 19 (4.0) 0.219
Hypertension 57 (25.0) 172 (36.1) 0.003
Diabetes mellitus 29 (12.7) 116 (24.4) <.001
Pulmonary disease 4 (1.8) 35 (7.4) 0.002
Stroke 4 (1.8) 27 (5.7) 0.018
Other neurological disease 7 (3.1) 35 (7.4) 0.025
Renal disease 4 (1.8) 37 (7.8) 0.001
Liver cirrhosis 1 (0.4) 9 (1.9) 0.180
Malignancy 5 (2.2) 14 (2.9) 0.567
Resuscitation variables
Witnessed arrest 182 (79.8) 290 (60.9) <.001
Bystander CPR 85 (37.3) 121 (25.4) 0.001
First monitored rhythm <.001
VF/pulseless VT 148 (64.9) 89 (18.7)
Pulseless electrical activity 28 (12.3) 77 (16.2)
Asystole 41 (17.9) 299 (62.8)
Unknown 11 (4.8) 11 (2.3)
Cardiac cause of arrest 201 (88.2) 232 (48.7) <.001
Time from arrest to ROSC, min 24.5 (16.5–34.5) 33 (25–45) <.001
Post-resuscitation variables
Initial Glasgow coma scale ≥5 76 (33.3) 23 (4.8) <.001
Initial presence of pupillary light reflex 178 (78.1) 132 (27.7) <.001
ST-elevation myocardial infarction 36 (15.8) 26 (5.5) <.001
Cardiogenic shockb 64 (28.1) 127 (26.7) 0.698
Thrombolysis 2 (0.9) 3 (0.6) 0.661
Coronary angiography 152 (66.7) 50 (10.5) <.001
Percutaneous coronary intervention 44 (19.3) 25 (5.3) <.001
Coronary artery bypass graft 7 (3.1) 0 (0.0) <.001
Intra-aortic balloon pump 8 (3.5) 11 (2.3) 0.359
Extracorporeal membrane oxygenation 4 (1.8) 10 (2.1) 1.000
Continuous renal replacement therapy 4 (1.8) 49 (10.3) <.001
Time from arrest to initiation of cooling, min 142 (81.5–247.5) 140 (80–240) 0.629
Time from arrest to 34 °C, min 385 (257.5–570) 307 (200–2454.5) <.001
Rewarming time, min 666 (420–780) 720 (480–990) 0.002
Data are presented as medians (interquartile range) or counts (percentage)
CPC cerebral performance category, CPR cardiopulmonary resuscitation, VF ventricular fibrillation, VT ventricular tachycardia, ROSC return of spontaneous circulation
aAbsence of the listed diseases
bHypotension (SBP <90 mmHg or MAP <60 mmHg for at least 30 min or the need for supportive measures (fluid loading and vasopressors or inotropic or both) to
maintain a SBP >90 mmHg or MAP >60 mmHg) and end-organ hypoperfusion (cool extremities)
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Table 2 Multivariable predictive model for poor neurological
outcomes at the time of hospital discharge
Variables OR (95 % CI) p
Continuous renal replacement therapya 5.66 (1.85–21.97) 0.005
Non-shockable initial rhythmb 2.97 (1.72–5.16) 0.009
Non-cardiac cause of arrestc 2.73 (1.47–5.17) 0.002
Previously unhealthyd 2.07 (1.20–3.60) 0.001
Time from arrest to ROSCe 1.06 (1.04–1.08) <.001
Agef 1.03 (1.01–1.05) 0.001
Initial Glasgow coma scale ≥5g 0.29 (0.14–0.58) 0.001
Initial presence of pupillary light reflexh 0.28 (0.17–0.46) <.001
Coronary angiographyi 0.13 (0.14–0.58) <.001
OR odds ratio, 95 % CI 95 % confidence interval, ROSC return of
spontaneous circulation
aNo continuous renal replacement therapy as reference
bVF/pulseless VT as reference
cCardiac cause of arrest as reference
dAbsence of the listed diseases as reference
eBy minute
fBy year
g < 5 as reference
hAbsence of pupillary light reflex as reference
iNo coronary angiography as reference
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consistent with the findings of the primary analysis.
To the best of our knowledge, this is the largest observa-
tional study to evaluate the association of AEs occurring
during TTM and the advanced critical care period with
neurological outcome at hospital discharge in adult OHCA
patients treated with TTM. Although we were only able to
investigate neurological outcome at hospital discharge, the
outcomes reported in our study may represent the natural
course of OHCA patients treated with TTM in the
hospitals because WLST based on prognostication was
not applied to these patients.
The results of neurological outcome among our survi-
vors were quite different from those observed in previous
studies performed in Western countries [11, 18, 19].
Compared to the results of prospective observational
studies by Nielsen et al. [18, 19], in which only a few
patients (1 %) exhibited CPC 4, 214 patients (30.4 %)
exhibited CPC 4 in our study. In the Target Temperature
Management trial, only 19 (4 %) patients at hospital
discharge and 6 (1 %) patients at 6 months had CPC
4 [11]. These differences may result from the difference
in baseline patients’ characteristics, especially certain
resuscitation-related variables, lower rate of WLST in our
study population, and difference in end points between two
studies (at 6 months versus at hospital discharge). Because
prehospital chains are relatively weak in South Korea,
resuscitation variables such as witnessed arrest, bystander
CPR, and initial rhythm were different in our study
compared to previous studies performed in Western
countries. In prospective observational studies fromEurope and North America, the proportions of witnessed
arrest, bystander CPR, and initial shockable rhythm were
higher than those in our study [11, 18, 19]. In contrast to
the rate of WLST in Western countries, where WLST is
the most common reason for death among cardiac arrest
survivors [5, 27], the rate of WLST is very low in South
Korea due to local cultural factors. Regardless of neuro-
logical status or the results of prognostication tests, most
family members choose to continue care for comatose
survivors resuscitated from cardiac arrest. Although the
Korean Medical Association recommended consensus
guidelines in 2009, WLST remains a matter of debate,
and WLST for post-cardiac arrest patients based on
prognostication is not legally permitted in South Korea.
This circumstance provides an excellent opportunity to
collect unbiased data on the association between prognos-
tic factors including AEs and ultimate neurological
outcomes in the modern intensive care setting. One
of the most valuable results of our study is the generation
of a multivariable predictive model of poor neurological
outcome at the time of hospital discharge. Because this
model was fitted to data in which WLST was not per-
formed, our results address a critical limitation of most
modern studies from Europe and North America.
Bleeding during TTM was rare in our study, and its
incidence was similar to that of most previous reports
[7, 11, 16–20]. Bleeding during TTM was more frequently
observed in patients receiving an invasive intervention,
such as IABP, extracorporeal membrane oxygenation
(ECMO), and cardiogenic shock, whereas thrombolysis
and the use of an endovascular device, coronary angiog-
raphy, or percutaneous coronary intervention (PCI) were
not associated with an increased risk of bleeding based on
univariate analysis. These results do not correspond to the
findings of the prospective study by Nielsen et al., in
which thrombolysis and the use of an endovascular device
were associated with an increased risk of bleeding based
on univariate analysis [19]. However, bleeding was not
significantly associated with the outcome in either
study. These results are consistent with the conclusion of
a recent systematic review and meta-analysis of the risk of
bleeding [28].
The incidence of newly developed arrhythmia during
TTM was slightly lower than that observed in previous
studies [11, 19, 29, 30]. Because we only retrospectively
collected the arrhythmia data during the TTM period,
the incidence observed in this study could be lower than
that observed by others. Recently, bradycardia during
TTM has been suggested to be a predictor of favorable
outcome [29, 30]. In our study, bradycardia during the
cooling period more frequently developed in patients with
good neurological outcome based on univariate analysis.
However, after adjusting for independent predictors of poor
neurological outcome, bradycardia was not significantly
Table 3 Adverse events and concomitant treatments with corresponding odds ratios for poor neurological outcomes at the time of
hospital discharge
Category AEs and concomitant
treatments




OR (95 % CI) p Adjusted
OR (95 % CI)
p
704 (100) 228(32.4) 476 (67.6)
Cooling -related AEs Overcoolinga 128 (18.2) 23 (10.1) 105 (22.1) 2.52 (1.56–4.09) <.001 1.16 (0.58–2.31) 0.681
Bradycardiab 83 (11.8) 35 (15.4) 48 (10.1) 0.62 (0.39–0.99) 0.044 0.75 (0.37–1.53) 0.429
Tachyarrhythmia 67 (9.5) 24 (10.5) 43 (9.0) 0.84 (0.50–1.43) 0.528 0.72 (0.33–1.55) 0.398
Hypokalemiac 220 (31.3) 65 (28.5) 155 (32.6) 1.21 (0.86–1.71) 0.278 1.21 (0.71–2.04) 0.486
Hyperglycemiad 321 (45.6) 81 (35.5) 240 (50.4) 1.85 (1.33–2.56) <.001 1.37 (0.84–2.24) 0.210
Bleeding 21 (3.0) 6 (2.6) 15 (3.2) 1.20 (0.46–3.15) 0.705 0.89 (0.21–3.71) 0.872
Hypotensione 204 (29.0) 54 (23.7) 150 (31.5) 1.48 (1.03–2.13) 0.033 1.03 (0.59–1.79) 0.926
Rewarming -related AEs Rebound hyperthermiaf 85 (12.1) 29 (12.7) 56 (11.8) 0.92 (0.57–1.48) 0.716 1.33 (0.61–2.92) 0.473
Arrhythmia 42 (6.0) 10 (4.4) 32 (6.7) 1.57 (0.76–3.25) 0.224 1.70 (0.61–4.69) 0.308
Hyperkalemiag 48 (6.8) 7 (3.1) 41 (8.6) 2.96 (1.31–6.74) 0.009 1.09 (0.37–3.19) 0.881
Hypoglycemiah 70 (9.9) 22 (9.7) 48 (10.7) 1.05 (0.62–1.79) 0.858 1.14 (0.50–2.57) 0.762
Bleeding 14 (2.0) 3 (1.3) 11 (2.3) 1.77 (0.49–6.41) 0.383 1.05 (0.18–6.06) 0.956
Hypotensione 152 (21.6) 36 (15.8) 116 (24.4) 1.72 (1.14–2.60) 0.01 0.99 (0.54–1.83) 0.984
Other AEs during advanced critical
care Concomitant treatments
Pneumoniai 279 (39.6) 70 (30.7) 209 (43.9) 1.77 (1.26–2.47) <.001 1.05 (0.63–1.74) 0.852
Sepsis 100 (14.2) 17 (7.5) 83 (17.4) 2.62 (1.52–4.53) <.001 3.12 (1.40–6.97) 0.005
Myoclonusj 154 (21.9) 34 (14.9) 120 (25.2) 1.92 (1.27–2.92) 0.002 3.72 (1.93–7.16) <.001
Seizurek 153 (21.7) 24 (10.5) 129 (27.1) 3.16 (1.98–5.05) <.001 4.02 (2.04–7.91) <.001
Hypoglycemial 162 (23.0) 36 (15.8) 126 (26.5) 1.92 (1.27–2.89) 0.002 2.03 (1.09–3.78) 0.025
Anticonvulsants 287 (40.8) 71 (31.1) 216 (45.4) 1.84 (1.32–2.56) <.001 1.69 (1.03–2.77) 0.039
Insulin 460 (65.3) 136(59.7) 324 (68.1) 1.44 (1.04–2.00) 0.028 0.98 (0.60–1.62) 0.944
Analgesics 323 (45.9) 122 (53.5) 201 (42.2) 0.64 (0.46–0.87) 0.005 0.75 (0.46–1.21) 0.239
Sedatives 657 (93.3) 222 (97.4) 435 (91.4) 0.29 (0.12–0.69) 0.005 0.92 (0.29–2.96) 0.888
Neuromuscular
blockers
475 (67.5) 174 (76.3) 301 (63.2) 0.53 (0.37–0.76) 0.001 0.48 (0.28–0.84) 0.009
AEs adverse events, CPC cerebral performance category, OR odds ratio, 95 % CI 95 % confidence interval
a < 32 °C
bHeart rate <40 bpm
c ≤ 3.0 mEq/L
d ≥ 180 mg/Dl
eSBP <90 mmHg or MAP <60 mmHg for at least 30 min or the need for supportive measures (fluid loading and vasopressors or inotropic or both) to maintain a
SBP >90 mmHg or MAP >60 mmHg
f > 38 °C within 24 hours of the cessation of cooling
g ≥ 5.0 mEq/L
h ≤ 80 mg/dL
iFour requirements: 1) new or progressive consolidation on the chest radiograph, 2) fever, 3) leukocytosis, and 4) the presence of purulent
tracheobronchial secretions
jClinically involuntary movement without epileptiform discharge on EEG
kEither clinically involuntary movement with epileptiform discharge on electroencephalogram (EEG) or epileptiform discharge only on EEG
l ≤ 80 mg/dL within 72 hours after ROSC
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discharge.
Hypotension during TTM was common but was not
significantly associated with poor neurological outcome
at hospital discharge after adjusting for independent pre-
dictors in our study. This finding is consistent with the
results of a previous study showing that MAP time inte-
gral during TTM were not significantly associated with
functional outcome at hospital discharge [31]. However,
the impact of hypotension during TTM on functionaloutcome is controversial. Many studies showed that early
hypotension (at the time of admission or during the first
6 hours after ROSC) and need for persisted vasopressor
support during TTM was significantly associated with poor
outcome [32–34]. Although hypotension during TTM was
not associated with poor neurological outcome in our
study, any conclusions based on our results should be
made with caution because the cause of hypotension is
multifactorial and because persistent or severe hypotension
during TTM is generally rare.
Table 4 Factors associated with selected adverse events in univariate analyses
Adverse event Factors OR (95 % CI) p
Bleeding Intra-aortic balloon pump 5.40 (1.47–19.83) 0.011
Continuous renal replacement therapy 3.13 (1.13–8.65) 0.028
Cardiogenic shocka 2.39 (1.09–5.26) 0.031
Pneumoniab Ice bag only 3.00 (1.79–5.02) <.001
Malignancy 2.68 (1.04–6.90) 0.041
Neurological disease 2.36 (1.25–4.46) 0.008
Non-shockable initial rhythm 1.58 (1.14–2.20) 0.006
No bystander cardiopulmonary resuscitation 1.45 (1.03–2.03) 0.033
Non-cardiac cause of arrest 1.44 (1.06–1.96) 0.021
Initial presence of pupillary light reflex 0.57 (0.42–0.78) <.001
ST-elevation myocardial infarction 0.55 (0.31–0.98) 0.042
Coronary angiography 0.51 (0.36–0.73) <.001
Angina pectoris 0.49 (0.25–0.95) 0.035
Percutaneous coronary intervention 0.47 (0.26– 0.82) 0.008
Initial Glasgow coma scale (≥5) 0.44 (0.27– 0.72) 0.001
Sepsis Intra-aortic balloon pump 3.71 (1.43–9.67) 0.007
Ice bag only 2.17 (1.20–3.94) 0.010
Unwitnessed arrest 2.11 (1.37–3.24) 0.001
No bystander cardiopulmonary resuscitation 1.78 (1.06–2.99) 0.030
Cardiogenic shocka 1.72 (1.10–2.68) 0.017
Non-cardiac cause of arrest 1.65 (1.08–2.53) 0.021
Coronary angiography 0.58 (0.35–0.98) 0.040
Myoclonusc Ice bag only 2.40 (1.42–4.05) 0.001
Hydrogel pad 1.58 (1.05–2.38) 0.027
ST-elevation myocardial infarction 0.36 (0.15–0.85) 0.019
Cooling garment 0.06 (0.01–0.45) 0.006
Seizured Congestive heart failure 2.68 (1.17–6.17) 0.020
Non-shockable initial rhythm 1.51 (1.01–2.25) 0.043
Endovascular cooling 0.64 (0.42–0.97) 0.035
Coronary angiography 0.54 (0.35–0.83) 0.005
Initial Glasgow coma scale≥ 5 0.32 (0.16–0.65) 0.002
Hypoglycemiae Continuous renal replacement therapy 2.59 (1.45–4.62) 0.001
Renal disease 2.53 (1.32–4.84) 0.005
Non-shockable initial rhythm 2.06 (1.37–3.11) <.001
Coronary angiography 0.65 (0.43–0.98) 0.039
Hydrogel pad 0.55 (0.34–0.88) 0.013
Percutaneous coronary intervention 0.47 (0.23–0.98) 0.042
Cooling garment 0.25 (0.09–0.70) 0.008
OR odds ratio, 95 % CI 95 % confidence interval
aHypotension (SBP <90 mmHg or MAP <60 mmHg for at least 30 min or the need for supportive measures (fluid loading and vasopressors or inotropic or both) to
maintain a SBP >90 mmHg or MAP >60 mmHg) and end-organ hypoperfusion (cool extremities)
bFour requirements: 1) new or progressive consolidation on the chest radiograph, 2) fever, 3) leukocytosis, 4) presence of purulent tracheobronchial secretions
cClinically involuntary movement without epileptiform discharge on EEG
dEither clinically involuntary movement with epileptiform discharge on EEG or epileptiform discharge only on EEG
e ≤ 80 mg/dL within 72 hours after ROSC
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observed during the cooling period [35, 36]. Although
overcooling during the cooling period was associated
with poor neurological outcome based on univariate
analysis, no such association was observed based on
multivariate analysis in our study. The incidence (12 %) of
rebound hyperthermia in our study was relatively lower
than that in previous reports of post-hypothermia fever
[37–40]. This discrepancy may be related to the differences
in the definitions of temperature level, observation
period and different populations between the compared
studies. In our study, which defined post-hypothermia
fever (>38 °C) within 24 hours of the cessation of cooling,
rebound hyperthermia was not associated with poor
neurological outcome based on either univariate or
multivariate analysis. The influence of post-hypothermia
fever on functional outcome is controversial [41, 42].
Therefore, further research on these temperature control-
related AEs is necessary.
The incidence (39.6 %) of pneumonia during the
advanced critical care period was similar to that
described in most previous reports, including studies of
cardiac arrest patients treated with TTM [7, 17, 18].
However, in some studies, the pneumonia incidence
was higher than our result [11, 19, 43]. Differences in
definitions, the use of prophylactic antibiotics, and
the rate of WLST between studies may explain these
discrepancies in the pneumonia incidence. In a recent
report, prophylactic antibiotic use was associated with
a lower incidence of pneumonia but did not appear
to influence mortality or functional outcome in cardiac
arrest survivors treated with TTM [44]. Because most
participating hospitals in our registry used prophylactic
antibiotics in their protocols, the incidence of pneumonia
in our study may be lower than that in other studies
[11, 19, 43]. However, the impact of prophylactic antibiotic
use on functional outcome could not be evaluated because
data concerning antibiotic use were not available in our
registry. Thus, further studies are needed to investigate
whether prophylactic antibiotic use impacts functional
outcome.
The incidence (14 %) of sepsis during the advanced
critical care period in our study was relatively higher
than that in previous studies [16, 18, 19]. A retrospective
study showed a similar incidence (13 %), and septic
events had no impact on neurological outcome at
hospital discharge [43]. In our study, after adjusting
for independent predictors of poor neurological outcome,
sepsis, but not pneumonia, was significantly associated
with poor neurological outcome. In a recent systematic
review and meta-analysis of TTM induced in adults
for any indication, TTM was strongly associated with
an increased risk of pneumonia and sepsis [45]. Most
studies and meta-analyses including cardiac arrest patientsshowed that pneumonia and sepsis may be more frequent
after TTM but that there were no significant differences
in mortality or neurological outcomes between subjects
undergoing TTM and normothermia or maintenance at
36 °C [11, 16, 17]. In a prospective observational study
including OHCA patients in Europe and North America,
pneumonia and sepsis were inversely associated with
mortality at 6 months based on univariate analysis
[19]. The authors interpreted that the association of
infections with mortality is possibly related to an increased
risk of infection during a longer length of stay, which has
been associated with a more favorable outcomes.
However, pneumonia and sepsis were more frequent
in patients with poor neurological outcome than in
those with good neurological outcome in our study.
The discrepancies between these two studies may be
explained by the difference in the rate of WLST. The
length of stay of the patients not awakening after sedation
was typically longer than that of the patients who woke up
after sedation was withdrawn because WLST was not
performed in our study.
Hypokalemia and hyperglycemia during the cooling
period were also frequently observed in our study, and
these findings were consistent with those of previous
reports [17–19]. Hypokalemia during the cooling period
was not associated with poor neurological outcome, and
this result was consistent with those of previous reports
[17, 19]. Hyperglycemia was associated with an increased
incidence of poor outcome in patients who were not
treated with TTM [46–48]. However, the influence of
the blood glucose level during TTM and the advanced
critical care period is uncertain. Sustained hyperglycemia
(>8 mmol/L or >144 mg/dL for >4 hours during the
critical care period) was associated with increased
mortality at 6 months in a prospective observational study
of OHCA patients treated with TTM [19]. However,
increased variability in the glucose level, but not the mean
blood glucose level, during TTM was found to be an
independent risk factor of in-hospital mortality in a
prospective observational study [49]. In a recent large
registry study that included OHCA patients treated
with TTM, an increased median blood glucose level
(>8.4 mmol/L or >152 mg/dL) over the first 48 hours
was associated with poor neurological outcome [50].
In our study, hyperglycemia (>180 mg/dL) during the
cooling period was associated with poor neurological
outcome based on univariate analysis but not multivariate
analysis. Our results suggest that a single recording of a
high blood glucose level during the cooling period may
not be an independent risk factor of poor neurological
outcome.
Notably, the incidence of hypoglycemia (<4.4 mmol/L
or <80 mg/dL) within 72 hours after ROSC was high
(23 %) in our study and was significantly associated with
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on both univariate and multivariate analysis. These
incidences were quite different from the results of the
Target Temperature Management trial and an observa-
tional study (5.5 % and 5 %, respectively) in which
hypoglycemia was defined at a lower level (<3.0 mmol/L
or <54 mg/dl) than our definition [11, 19]. In the observa-
tional study, hypoglycemia during the critical care period
was associated with increased mortality at 6 months based
on univariate analysis but not multivariate analysis [19].
The reasons for the high incidence of hypoglycemia within
72 hours after ROSC in our study may be very com-
plex. The lack of feeding, the use of intensive insulin
therapy prior to the publication of the 2010 guidelines,
and increased insulin sensitivity during rewarming may
have influenced the high incidence of post-rewarming
hypoglycemia within 72 hours after ROSC. Most hospitals
that participated in our registry used no feeding protocol
within 72 hours after ROSC because TTM may impair
intestinal motility [15]. In a recent multicenter retro-
spective analysis, insulin sensitivity consistently increased
over the first 36 hours [51]. Although the optimal level
and duration of glycemic control during post-cardiac
arrest care remains controversial, our results suggest that
hypoglycemia within 72 hours after ROSC, even just
below the normal range, may be harmful and may nega-
tively impact neurological outcome because the injured
brain is more sensitive to the glucose supply. Our results
may support the recommendation of maintaining the
blood glucose levels between 144 and 180 mg/dL based
on the hypoglycemic risk of strict glucose control in the
current guidelines [8, 9]. Our findings suggest that the
careful monitoring and prevention of hypoglycemia are
important within 72 hours after ROSC.
The incidences of seizure and myoclonus during the
advanced critical care period were high in our study and
were similar to those of previous reports, which ranged
from 15 to 44 % [11, 19, 52, 53]. Seizure and myoclonus
during the advanced critical care period were strongly
associated with poor neurological outcome based on
both univariate and multivariate analysis in our study, and
these results were consistent with the results of previous
studies [20, 54, 55]. Although anticonvulsant use was
significantly associated with poor neurological outcome,
this may not serve as an independent variable but rather
may be collinear with seizure and myoclonus because
most physicians in the participating hospitals in our
registry only administered anticonvulsants when seizure
or myoclonus was observed or highly suspected. The
observed correlation between the use of anticonvulsants
and poor outcome does not represent convincing evidence
that this treatment contributes to poor outcome because
patients with seizure after ROSC have likely experienced a
major neurological injury.Although seizure and myoclonus were strongly associated
with poor neurological outcome, recent reports have sug-
gested that some patients treated with TTM who experi-
ence seizure or myoclonus exhibit good neurological
outcome [19, 56, 57]. In our study, 22 % of patients with
myoclonus, 16 % of patients with seizure, and 25 %
of patients treated with anticonvulsants exhibited good
neurological outcome at the time of hospital discharge.
These results were similar to the result that 17 % of OHCA
patients with seizures exhibited good outcomes at 6 months
in a previous observational study [19]. Therefore, careful
monitoring and aggressive treatment of these AEs may be
important for improving functional outcome.
An additional interesting finding in our study was the
inverse association between NMB use during TTM and
poor neurological outcome at hospital discharge. This
result may support the hypothesis of Salciccioli et al.
[58], who reported that early continuous NMB use for a
24-hour period is associated with an increased probability
of survival among post-cardiac arrest patients. In their
study, NMB use showed a trend toward improved func-
tional outcome, although this result was not statistically
significant. Although we did not consider the NMB type,
NMB delivery protocol, or duration of NMB adminis-
tration, our result generates the following hypotheses
for future research: patients with poor neurological out-
come need less NMB use for shivering control, and NMB
use during the early post-cardiac arrest care period may
improve functional outcome.
Limitations
There were several limitations to our study. First,
although we attempted to collect all consecutive OHCA
patients who were treated with TTM in each hospital
during the study period, there was an inevitable risk of
selection bias because our study employed a retrospective
design. Second, although we employed a standard investi-
gation protocol, verified data completeness according to
the site principle investigators, and used a team to
perform data quality control, our study was subject to
reporting bias because it was a registry-based multicenter
study. Furthermore, the variability in TTM implementa-
tion timing and in the TTM protocol among hospitals
may have impact the incidences of AEs and outcomes.
Third, some of the AEs defined as other AEs, such as
pneumonia and sepsis, may be considered cooling- or
rewarming-related AEs. However, these AEs are difficult
to diagnose during TTM and were recorded as other AEs
during the advanced critical care period. Thus, our study
cannot determine whether pneumonia or sepsis occurring
during the cooling or rewarming period is associated with
poor neurological outcome. Fourth, the data used in this
study were collected from teaching hospitals in an
Asian country; therefore, our results may have limited
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neurological outcome at the time of hospital discharge,
and this variable was not adequately blinded. This end
point, which is not the current standard, may be not
a reliable indicator of long-term outcome, although
some investigators have suggested that the CPC score
at the time of hospital discharge is a useful surrogate
measure of long-term outcome [59].
Conclusions
In this retrospective study using multicenter registry data,
cooling- and rewarming-related AEs were not associated
with poor neurological outcome at the time of hospital
discharge in OHCA patients treated with TTM. However,
sepsis, myoclonus, seizure, hypoglycemia within 72 hours
after ROSC, and the use of anticonvulsants during the
advanced critical care period were significantly associated
with poor neurological outcome at the time of hospital
discharge in our study.
Key messages
 In this multicenter, registry-based study of adult
OHCA patients treated with TTM in whom WLST
was not performed, older age, previous poor health,
a non-shockable initial rhythm, a longer time from
arrest to ROSC, a non-cardiac cause of arrest, and
CRRT were independent predictors of poor
neurological outcome at the time of hospital
discharge. Alternatively, initial GCS score ≥5, initial
presence of the pupillary light reflex, and coronary
angiography were inversely associated with poor
neurological outcome.
 After adjusting for independent predictors of poor
neurological outcome, cooling- and rewarming-related
AEs were not significantly associated with poor
neurological outcome at the time of hospital discharge.
 After adjusting for independent predictors of poor
neurological outcome, sepsis, myoclonus, seizure,
hypoglycemia within 72 hours after ROSC, and the
use of anticonvulsants during the advanced critical
care period were significantly associated with poor
neurological outcome at the time of hospital
discharge.
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